Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy

Nature Genetics

Volumn 47, Issue 2, 2015, Pages 180-185

  Zhang, Michael Y ^a   Churpek, Jane E ^b   Keel, Siobán B ^c   Walsh, Tom ^c,d   Lee, Ming K ^c,d   Loeb, Keith R ^a,c   Gulsuner, Suleyman ^c,d   Pritchard, Colin C ^c   Sanchez Bonilla, Marilyn ^a   Delrow, Jeffrey J ^a   Basom, Ryan S ^a   Forouhar, Melissa ^e   Gyurkocza, Boglarka ^a   Schwartz, Bradford S ^f,g   Neistadt, Barbara ^b   Marquez, Rafael ^b   Mariani, Christopher J ^b   Coats, Scott A ^a   Hofmann, Inga ^h,i,j   Lindsley, R Coleman ^k,l   Williams, David A ^h,i,j   Abkowitz, Janis L ^c   Horwitz, Marshall S ^c   King, Mary Claire ^c,d   Godley, Lucy A ^b   Shimamura, Akiko ^a,d,m   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e MADIGAN ARMY MEDICAL CENTER   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j HARVARD STEM CELL INSTITUTE   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m SEATTLE CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR ETV6; RECOMBINANT PROTEIN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR ETS;

ADOLESCENT; ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; CHILD; CYTOPENIA; DISEASE PREDISPOSITION; DNA BINDING; FAMILIAL DISEASE; FAMILIAL THROMBOCYTOPENIA; GENETIC VARIABILITY; GERMLINE MUTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MIDDLE AGED; MISSENSE MUTATION; NONHUMAN; PATIENT RISK; PRIORITY JOURNAL; SCHOOL CHILD; SOMATIC MUTATION; THROMBOCYTOPENIA; VERY ELDERLY; CELL PROLIFERATION; CHEMICAL STRUCTURE; EXON; FEMALE; GENETICS; HELA CELL LINE; HEMATOLOGIC DISEASE; MALE; MOLECULAR GENETICS; PEDIGREE; PROTEIN TERTIARY STRUCTURE; REPORTER GENE; SEQUENCE ANALYSIS;

CELL PROLIFERATION; EXONS; FEMALE; GENES, REPORTER; GERM-LINE MUTATION; HELA CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PEDIGREE; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ETS; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, RNA; THROMBOCYTOPENIA;

EID: 84926216729     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3177     Document Type: Article

References (58)

1. Song, W.-J. et al. Haploinsuffciency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23, 166-175 (1999).
2. Smith, M.L., Cavenagh, J.D., Lister, T.A. & Fitzgibbon, J. Mutation of CEBPA in familial acute myeloid leukemia. N. Engl. J. Med. 351, 2403-2407 (2004).
3. Hahn, C.N. et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat. Genet. 43, 1012-1017 (2011).
4. Kazenwadel, J. et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood 119, 1283-1291 (2012).
5. Pippucci, T. et al. Mutations in the 5′ UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am. J. Hum. Genet. 88, 115-120 (2011).
6. Noris, P. et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood 117, 6673-6680 (2011).
7. Kirwan, M. et al. Exome sequencing identifes autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. Am. J. Hum. Genet. 90, 888-892 (2012).
8. Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226-1231 (2013).
9. Auer, F. et al. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547GA. Leukemia 28, 1136-1138 (2014).
10. Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242-252 (2013).
11. Powell, B.C. et al. Identifcation of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatr. Blood Cancer 60, E1-E3 (2013).
12. Zhang, M.Y. et al. Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. Haematologica doi:10.3324/haematol.2014.113456 (19 September 2014).
13. De, S. et al. Steric mechanism of auto-inhibitory regulation of specifc and non-specifc DNA binding by the ETS transcriptional repressor ETV6. J. Mol. Biol. 426, 1390-1406 (2014).
14. Biasini, M. et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 42, W252-W258 (2014).
15. Green, S.M., Coyne, H.J. III, McIntosh, L.P. & Graves, B.J. DNA binding by the ETS protein TEL (ETV6) is regulated by autoinhibition and self-association. J. Biol. Chem. 285, 18496-18504 (2010).
16. Coyne, H.J. et al. Autoinhibition of ETV6 (TEL) DNA binding: appended helices sterically block the ETS domain. J. Mol. Biol. 421, 67-84 (2012).
17. Chakrabarti, S.R. & Nucifora, G. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. Biochem. Biophys. Res. Commun. 264, 871-877 (1999).
18. Park, H., Seo, Y., Kim, J.I., Kim, W. & Choe, S.Y. Identifcation of the nuclear localization motif in the ETV6 (TEL) protein. Cancer Genet. Cytogenet. 167, 117-121 (2006).
19. Fenrick, R. et al. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol. Cell. Biol. 19, 6566-6574 (1999).
20. Fenrick, R. et al. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of Ras-transformed cells while repressing the transcription of stromelysin-1. Mol. Cell. Biol. 20, 5828-5839 (2000).
21. Lopez, R.G. et al. TEL is a sequence-specifc transcriptional repressor. J. Biol. Chem. 274, 30132-30138 (1999).
22. Kwiatkowski, B.A. et al. The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity. J. Biol. Chem. 273, 17525-17530 (1998).
23. Kim, C.A. et al. Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression. EMBO J. 20, 4173-4182 (2001).
24. Wang, L.C. et al. The TEL/ETV6 gene is required specifcally for hematopoiesis in the bone marrow. Genes Dev. 12, 2392-2402 (1998).
25. Hock, H. et al. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev. 18, 2336-2341 (2004).
26. Pritchard, C.C. et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J. Mol. Diagn. 16, 56-67 (2014).
27. Marquez, R. et al. A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk. Lymphoma doi:10.3109/10428194. 2014.903476 (22 April 2014).
28. Novershtern, N. et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144, 296-309 (2011).
29. Bluteau, D. et al. Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. J. Clin. Invest. 124, 580-591 (2014).
30. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
31. Seshagiri, S. et al. Recurrent R-spondin fusions in colon cancer. Nature 488, 660-664 (2012).
32. Welch, J.S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264-278 (2012).
33. Walter, M.J. et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 27, 1275-1282 (2013).
34. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012).
35. Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496-2506 (2011).
36. + hematopoietic cells in myelodysplastic syndrome and gene mutation profles as prognostic markers. Proc. Natl. Acad. Sci. USA 111, 8589-8594 (2014).
37. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012).
38. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69 (2011).
39. Dolnik, A. et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 120, e83-e92 (2012).
40. Padron, E. et al. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood 123, 3675-3677 (2014).
41. Griesinger, F., Janke, A., Podleschny, M. & Bohlander, S.K. Identifcation of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line. Br. J. Haematol. 119, 454-458 (2002).
42. Zhang, J. et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 118, 3080-3087 (2011).
43. Wang, Q. et al. ETV6 mutation in a cohort of 970 patients with hematologic malignancies. Haematologica 99, e176-e178 (2014).
44. Lohr, J.G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91-101 (2014).
45. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
46. Walsh, T. et al. Whole exome sequencing and homozygosity mapping identify mutation in the cell polarity protein GPSM2 as the cause of non-syndromic hearing loss DFNB82. Am. J. Hum. Genet. 87, 90-94 (2010).
47. Gulsuner, S. et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 154, 518-529 (2013).
48. Walsh, T. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identifed by massively parallel sequencing. Proc. Natl. Acad. Sci. USA 108, 18032-18037 (2011).
49. Mostoslavsky, G., Fabian, A.J., Rooney, S., Alt, F.W. & Mulligan, R.C. Complete correction of murine Artemis immunodefciency by lentiviral vector-mediated gene transfer. Proc. Natl. Acad. Sci. USA 103, 16406-16411 (2006).
50. Delaney, C., Varnum-Finney, B., Aoyama, K., Brashem-Stein, C. & Bernstein, I.D. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood 106, 2693-2699 (2005).
51. Trapnell, C., Pachter, L. & Salzberg, S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
52. Anders, S., Pyl, P.T. & Huber, W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics doi:10.1093/bioinformatics/btu638 (25 September 2014).
53. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
54. Reiner, A., Yekutieli, D. & Benjamini, Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19, 368-375 (2003).
55. Yeung, K.Y., Haynor, D.R. & Ruzzo, W.L. Validating clustering for gene expression data. Bioinformatics 17, 309-318 (2001).
56. Saeed, A.I. et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34, 374-378 (2003).
57. Young, M.D., Wakefeld, M.J., Smyth, G.K. & Oshlack, A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 11, R14 (2010).
58. Burwick, N., Coats, S.A., Nakamura, T. & Shimamura, A. Impaired ribosomal subunit association in Shwachman-Diamond syndrome. Blood 120, 5143-5152 (2012).